|
|
|
|
FMC406
Digestive system carcinoma frozen tissue array, including TNM and clinical stage information, 40 cases/40 cores
|
|
| Microarray Panel: | Multiple organ carcinoma frozen tissue microarray, containing 30 cases of colon carcinoma, 2 esophagus carcinoma and 8 stomach carcinoma, single core per case |
| Cores: | 40 |
|
| Cases: | 40 |
| Layout: | 8 cols × 5 rows |
| Core Diameter: | 2 mm |
| Thickness: | 5 µm | | Quality Control: | Anti-Actin confirmed | | Applications: | Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page. |
| Notes: | Tissues were snap frozen in liquid nitrogen immediately after excision and were embedded in OCT. The array sections are 5-8 µm in thickness, mounted on positively charged glass slides, and briefly fixed by cold acetone. |
*Tissue Microarray Slide Types:
- Unstained: unstained
frozen
tissue microarray slide.
- Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
- H & E: Hematoxylin and Eosin stained tissue microarray slide.
Specification Sheet
| Pos |
No. |
Sex |
Age |
Organ |
Pathology diagnosis |
Stage |
TNM |
Type † |
|
A1 |
1 |
M |
40 |
Colon |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
A2 |
2 |
M |
52 |
Colon |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
A3 |
3 |
M |
67 |
Colon |
Adenocarcinoma |
I |
T2N0M0 |
Malignant |
|
A4 |
4 |
M |
66 |
Colon |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
A5 |
5 |
M |
40 |
Colon |
Adenocarcinoma (rectal mucosa tissue) |
II |
T3N0M0 |
Malignant |
|
A6 |
6 |
M |
57 |
Colon |
Adenocarcinoma (smooth muscle tissue) |
II |
T3N0M0 |
Malignant |
|
A7 |
7 |
M |
69 |
Colon |
Adenocarcinoma |
III |
T3N1M0 |
Malignant |
|
A8 |
8 |
F |
42 |
Colon |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
B1 |
9 |
M |
41 |
Colon |
Adenocarcinoma (rectum tissue) |
II |
T3N0M0 |
Malignant |
|
B2 |
10 |
M |
42 |
Colon |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
B3 |
11 |
F |
70 |
Colon |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
B4 |
12 |
M |
52 |
Colon |
Adenocarcinoma |
III |
T3N1M0 |
Malignant |
|
B5 |
13 |
M |
46 |
Colon |
Adenocarcinoma |
III |
T3N1M0 |
Malignant |
|
B6 |
14 |
M |
55 |
Colon |
Adenocarcinoma (sparse) |
II |
T3N0M0 |
Malignant |
|
B7 |
15 |
M |
59 |
Colon |
Adenocarcinoma (sparse) |
II |
T3N0M0 |
Malignant |
|
B8 |
16 |
M |
58 |
Colon |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
C1 |
17 |
M |
55 |
Colon |
Mucinous adenocarcinoma |
– |
– |
Malignant |
|
C2 |
18 |
F |
67 |
Colon |
Adenocarcinoma |
III |
T3N1M0 |
Malignant |
|
C3 |
19 |
M |
58 |
Colon |
Adenoma canceration |
I |
T3N0M0 |
Malignant |
|
C4 |
20 |
F |
39 |
Colon |
Squamous cell carcinoma (sparse) |
III |
T3N1M0 |
Malignant |
|
C5 |
21 |
F |
37 |
Colon |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
C6 |
22 |
M |
42 |
Colon |
Adenocarcinoma |
III |
T3N1M0 |
Malignant |
|
C7 |
23 |
M |
45 |
Colon |
Adenocarcinoma |
III |
T3N1M0 |
Malignant |
|
C8 |
24 |
M |
50 |
Colon |
Adenocarcinoma |
III |
T3N1M0 |
Malignant |
|
D1 |
25 |
M |
43 |
Colon |
Adenocarcinoma |
III |
T3N1M0 |
Malignant |
|
D2 |
26 |
M |
67 |
Colon |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
D3 |
27 |
M |
58 |
Colon |
Adenocarcinoma |
III |
T3N1M0 |
Malignant |
|
D4 |
28 |
M |
39 |
Colon |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
D5 |
29 |
M |
37 |
Colon |
Adenocarcinoma |
III |
T3N1M0 |
Malignant |
|
D6 |
30 |
F |
42 |
Colon |
Low grade malignant interstitialoma |
Ib |
T2N0M0 |
Malignant |
|
D7 |
31 |
M |
56 |
Esophagus |
Squamous cell carcinoma |
IIa |
T3N0M0 |
Malignant |
|
D8 |
32 |
M |
46 |
Esophagus |
Squamous cell carcinoma |
IIa |
T3N0M0 |
Malignant |
|
E1 |
33 |
M |
63 |
Stomach |
Squamous cell carcinoma (fibrofatty tissus) |
Ib |
T2N0M0 |
Malignant |
|
E2 |
34 |
M |
46 |
Stomach |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
E3 |
35 |
M |
52 |
Stomach |
Adenocarcinoma (sparse) |
II |
T3N0M0 |
Malignant |
|
E4 |
36 |
M |
53 |
Stomach |
Adenocarcinoma |
IIIa |
T3N1M0 |
Malignant |
|
E5 |
37 |
F |
46 |
Stomach |
Adenocarcinoma (sparse) |
IIIa |
T3N1M0 |
Malignant |
|
E6 |
38 |
F |
54 |
Stomach |
Mucinous adenocarcinoma |
IIIa |
T3N1M0 |
Malignant |
|
E7 |
39 |
F |
57 |
Stomach |
Adenocarcinoma |
II |
T3N0M0 |
Malignant |
|
E8 |
40 |
M |
61 |
Stomach |
Adenocarcinoma |
IIIa |
T3N1M0 |
Malignant |
† For precise diagnosis, refer to pathology description.
TNM Grading
Primary tumor (T)
- TX: Primary tumor cannot be assessed
- T0: No evidence of primary tumor
- Tis: Intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the nipple with no associated invasion of normal breast tissue
- Tis (DCIS): Ductal carcinoma in situ
- Tis (LCIS): Lobular carcinoma in situ
- Tis (Paget's): Paget's disease of the nipple with no tumor. [Note: Paget's disease associated with a tumor is classified according to the size of the tumor.]
- T1: Tumor 2.0 cm or less in greatest dimension
- T1mic: Microinvasion 0.1 cm or less in greatest dimension
- T1a: Tumor more than 0.1 but not more than 0.5 cm in greatest dimension
- T1b: Tumor more than 0.5 cm but not more than 1.0 cm in greatest dimension
- T1c: Tumor more than 1.0 cm but not more than 2.0 cm in greatest dimension
- T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension
- T3: Tumor more than 5.0 cm in greatest dimension
- T4: Tumor of any size with direct extension to (a) chest wall or (b) skin, only as described below.
- T4a: Extension to chest wall, not including pectoralis muscle
- T4b: Edema (including peau d'orange) or ulceration of the skin of the breast, or satellite skin nodules confined to the same breast
- T4c: Both T4a and T4b
- T4d: Inflammatory carcinoma.
- Memory Aid for Primary tumor: The two numbers to remember are 2.0 and 5.0
- T1 is no larger than 2.0 cm
- T2 > 2.0 - 5.0 cm
- T3 > 5.0 cm
Regional lymph nodes (N)
- NX: Regional lymph nodes cannot be assessed (e.g., previously removed)
- N0: No regional lymph node metastasis
- N1: Metastasis to movable ipsilateral axillary lymph node(s)
- N2: Metastasis to ipsilateral axillary lymph node(s) fixed or matted, or in clinically apparent* ipsilateral internal mammary notes in the absence of clinically evident lymph node metastasis
- N2a: Metastasis in ipsilateral axillary lymph nodes fixed to one another (matted) or to other structures
- N2b: Metastasis only in clinically apparent* ipsilateral internal mammary nodes and in the absence of clinically evident axillary lymph node metastasis.
- N3: Metastasis in ipsilateral infraclavicular lymph node(s) with or without axillary lymph node involvement, or in clinically apparent* ipsilateral internal mammary lymph node(s) and in the presence of clinically evident axillary lymph node metastasis; or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement
- N3a: Metastasis in ipsilateral infraclavicular lymph node(s)
- N3b: Metastasis in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)
- N3c: Metastasis in ipsilateral supraclavicular lymph node(s)
* [Note: Clinically apparent is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination or grossly visible pathologically.]
Distant metastasis (M)
- MX: Presence of distant metastasis cannot be assessed
- M0: No distant metastasis
- M1: Distant metastasis
|
|